참고문헌
- Alsdorf, R. and Wyszynski, D.F. (2005). Teratogenicity of sodium valproate. Expert Opin Drug Saf., 4, 345-353. https://doi.org/10.1517/14740338.4.2.345
- Binkerd, P.E., Rowland, J.M., Nau, H. and Hendrickx, A.G. (1988). Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl. Toxicol., 11, 485-493. https://doi.org/10.1016/0272-0590(88)90112-1
- Dickinson, R.G., Kaufman, S.N., Lynn, R.K., Cook, M.J., Novy, M.J. and Gerber, N. (1979). Materno-fetal pharmacokinetics and fetal distribution of valproic acid in the monkey. Proc. West. Pharmacol. Soc., 22, 57-61.
- Dickinson, R.G., Lawyer, C.H., Kaufman, S.N., Lynn, R.K., Gerber, N., Novy, M.J. and Cook, M.J. (1980). Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. Pediatr Pharmacol., 1, 71-83.
- Emmanouil-Nikoloussi, E.N., Foroglou, N.G., Kerameos-Foroglou, C.H. and Thliveris, J.A. (2004). Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie., 88, 41-45. https://doi.org/10.1016/S1286-0115(04)97999-4
- Hauck, R.S. and Nau, H. (1989). Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Tox. Lett., 49, 41-48. https://doi.org/10.1016/0378-4274(89)90099-4
- Hendrickx, A.G., Nau, H., Binkerd, P., Rowland, J.M., Rowland, J.R., Cukierski, M.J. and Cukierski, M.A. (1988) Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology, 38, 329-345. https://doi.org/10.1002/tera.1420380405
- Mast, T.J., Cukierski, M.A., Nau, H. and Hendrickx, A.G. (1986). Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology, 39, 111-119. https://doi.org/10.1016/0300-483X(86)90129-0
- Menegola, E., Broccia, M.L., Nau, H., Prati, M., Ricolfi, R. and Giavini, E. (1996). Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen., 16, 97-108. https://doi.org/10.1002/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A
- Nau, H. (1986). Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect., 70, 113-129. https://doi.org/10.2307/3430348
- Nau, H., Hauck, R.S. and Ehlers, K. (1991). Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol., 69, 310-21. https://doi.org/10.1111/j.1600-0773.1991.tb01303.x
- Ohdo, S., Ogawa, N., Nakano, S. and Higuchi, S. (1996). Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J. Pharmacol. Exp. Ther., 278, 74-81.
- Ornoy, A. (2006). Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol., 22, 214-226. https://doi.org/10.1016/j.reprotox.2006.03.014
- Ornoy, A. (2009). Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol., 28, 1-10. https://doi.org/10.1016/j.reprotox.2009.02.014
- Rettenmeier, A.W., Gordon, W.P., Prickett, K.S., Levy, R.H. and Baillie, T.A. (1986a). Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab Dispos., 14, 454-64.
- Rettenmeier, A.W., Gordon, W.P., Prickett, K.S., Levy, R.H., Lockard, J.S., Thummel, K.E. and Baillie, T.A. (1986b). Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab Dispos., 14, 443-453.
- Rosenberg, G. (2007). The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci., 64, 2090-2103. https://doi.org/10.1007/s00018-007-7079-x
- Semmes, R.L. and Shen, D.D. (1990). Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins. Pharm. Res., 5, 461-467.
- Tong, V., Teng, X.W., Chang, T.K and Abbott, F.S. (2005). Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci., 86, 427-435. https://doi.org/10.1093/toxsci/kfi184
- Vorhees, C.V. (1987). Teratogenicity and developmental toxicity of valproic acid in rats. Teratology, 35, 195-202. https://doi.org/10.1002/tera.1420350205
- Vorhees, C.V., Acuff-Smith, K.D., Weisenburger, W.P., Minck, D.R., Berry, J.S., Setchell, K.D. and Nau, H. (1991). Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats. Teratology, 43, 583-590. https://doi.org/10.1002/tera.1420430613
- Wide, K., Winbladh, B. and Källén, B. (2004). Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr., 93, 174-176. https://doi.org/10.1080/08035250310021118
피인용 문헌
- Milk Transfer and Toxicokinetics of Valproic Acid in Lactating Cynomolgus Monkeys vol.29, pp.1, 2013, https://doi.org/10.5487/TR.2013.29.1.053
- The protective effect of polyunsaturated fatty acid intake during pregnancy against embryotoxicity of sodium valproate in mice vol.9, pp.5, 2018, https://doi.org/10.1039/C7FO01604B